Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Federal Preemption Defense Under Fire In Draft House Bills

This article was originally published in The Gray Sheet

Executive Summary

A one-sentence provision tucked into draft legislation circulating in a House subcommittee seeks to weaken device and drug manufacturers' ability to claim FDA approval as a defense in state product liability lawsuits

You may also be interested in...



Controversy Persists Over House Pre-emption Provision

Device industry support for the House medical device user fee reauthorization bill is threatened by language that companies say would make them more vulnerable to patient lawsuits

Controversy Persists Over House Pre-emption Provision

Device industry support for the House medical device user fee reauthorization bill is threatened by language that companies say would make them more vulnerable to patient lawsuits

Industry Alarmed By Third-Party Audit, Registry Provisions In Draft House Bills

A House subcommittee released nine pieces of draft FDA legislation June 6, including several provisions that mobilized device industry lobbyists to fight for changes

Related Content

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel